The Silverstein Foundation In the News
The Silverstein Foundation has been featured in national and international publications and broadcast media. Explore the thinks below to see and hear what others are saying about the Foundation and our Founder’s story.
March, 2018: The Silverstein Foundation and MJFF Announce Availability of Research Funding
The Silverstein Foundation for Parkinson’s with GBA and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) Jointly Announce Availability of $3.5 Million in Fall 2018 Research Funding to Expand Understanding of the GBA gene in Parkinson’s...
Press Release: Prevail Therapeutics Announces $75 Million Series A Financing
Prevail Therapeutics, Inc. (Prevail), a biotechnology company developing gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases, today announced a $75 million Series A financing. Investors in the round included OrbiMed, Pontifax, RA Capital, EcoR1 Capital, Omega Funds, BVF Partners L.P., Boxer Capital LLC, Adage Capital Management L.P., and Alexandria Venture Investments. OrbiMed and the Silverstein Foundation for Parkinson’s with GBA incubated and provided seed funding to Prevail.
Press Release: March 8th Workshop on Accelerating Therapeutic Development in GBA-associated PD
New York, New York – March 8, 2018 – The Silverstein Foundation for Parkinson’s with GBA and the Michael J. Fox Foundation for Parkinson’s Research today held a joint workshop on accelerating therapeutic development for people with glucocerebrosidase(GBA)-associated Parkinson’s Disease. The meeting was held at the Michael J. Fox Foundation headquarters in New York City.
Forbes: Meet Top Top VC In a Race To Find His Own Parkinson’s Cure
April, 2017—Two decades of successful investing in some of biotech’s biggest hits has made Jonathan Silverstein rich. Now he is looking for investments that could save his life.
The Michael J. Fox Foundation for Parkinson’s Research: A Personal (and Professional) Mission to Cure Parkinson’s
August, 2017—Health care venture capitalist Jonathan Silverstein has more than two decades of professional experience with strategic investment in drug development. However, Jonathan’s sense of urgency to find cures intensified after he received a...